FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578265208> ?p ?o ?g. }

• W2578265208 endingPage "338" @default.
• W2578265208 startingPage "329" @default.
• W2578265208 abstract "Radiosynthesis and Pharmacokinetics of [18F]fluoroethyl bufalin in Hepatocellular Carcinoma bearing Mice Zhaoshuo Yang,1 Jianhua Liu,2 Qingqing Huang,3 Zhouji Zhang,1 Jiawei Zhang,1 Yanjia Pan,1 Yunke Yang,1 Dengfeng Cheng4 1Department of Chinese Traditional Medicine, Zhongshan Hospital, Fudan University, 2School of Medicine, Shanghai Jiao Tong University, 3Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, 4Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China Purpose: Bufalin, the main component of a Chinese traditional medicine chansu, shows convincing anticancer effects in a lot of tumor cell lines. However, its in vivo behavior is still unclear. This research aimed to evaluate how bufalin was dynamically absorbed after intravenous injection in animal models. We developed a radiosynthesis method of [18F]fluoroethyl bufalin to noninvasively evaluate the tissue biodistribution and pharmacokinetics in hepatocellular carcinoma-bearing mice. Methods: [18F]fluoroethyl bufalin was synthesized with conjugation of 18F-CH2CH2OTs and bufalin. The radiochemical purity was proved by the radio-high-performance liquid chromatography (HPLC). The pharmacokinetic studies of [18F]fluoroethyl bufalin were then performed in Institute of Cancer Research (ICR) mice. Furthermore, the biodistribution and metabolism of [18F]fluoroethyl bufalin in HepG2 and SMMC-7721 tumor-bearing nude mice were studied in vivo by micro-positron emission tomography (micro-PET). Results: The radiochemical purity (RCP) of [18F]fluoroethyl bufalin confirmed by radio-HPLC was 99%±0.18%, and [18F]fluoroethyl bufalin showed good in vitro and in vivo stabilities. Blood dynamics of [18F]fluoroethyl bufalin conformed to the two compartments in the ICR mice model. The pharmacokinetic parameters of [18F]fluoroethyl bufalin were calculated by DAS 2.0 software. The area under concentration–time curve (AUC0–t) and the values of clearance (CL) were 540.137 µg/L·min and 0.001 L/min/kg, respectively. The half-life of distribution (t1/2α) and half-life of elimination (t1/2β) were 0.693 and 510.223 min, respectively. Micro-PET imaging showed that [18F]fluoroethyl bufalin was quickly distributed via the blood circulation; the major tissue biodistribution of [18F]fluoroethyl bufalin in HepG2 and SMMC-7721 tumor-bearing mice was liver and bladder. Conclusion: [18F]fluoroethyl bufalin was accumulated rapidly in the liver at an early time point (5 min) post injection (pi) and then declined slowly, mainly through both the hepatic pathway and the renal pathway. Our study showed the biodistribution of [18F]fluoroethyl bufalin in micro-PET images and provided visible information for demonstrating the bioactivities of bufalin. Keywords: [18F]fluoroethyl bufalin, PET, hepatocellular carcinoma, pharmacokinetic, tissue biodistribution" @default.
• W2578265208 created "2017-01-26" @default.
• W2578265208 creator A5011634104 @default.
• W2578265208 creator A5030411354 @default.
• W2578265208 creator A5035915328 @default.
• W2578265208 creator A5041917929 @default.
• W2578265208 creator A5048100416 @default.
• W2578265208 creator A5054620758 @default.
• W2578265208 creator A5087541016 @default.
• W2578265208 creator A5091543149 @default.
• W2578265208 date "2017-01-01" @default.
• W2578265208 modified "2023-09-27" @default.
• W2578265208 title "Radiosynthesis and pharmacokinetics of [¹⁸F]fluoroethyl bufalin in hepatocellular carcinoma-bearing mice" @default.
• W2578265208 cites W1966802465 @default.
• W2578265208 cites W1967438857 @default.
• W2578265208 cites W1991071886 @default.
• W2578265208 cites W1999335450 @default.
• W2578265208 cites W2003426533 @default.
• W2578265208 cites W2009950502 @default.
• W2578265208 cites W2020436718 @default.
• W2578265208 cites W2032028265 @default.
• W2578265208 cites W2034129064 @default.
• W2578265208 cites W2039474933 @default.
• W2578265208 cites W2043152312 @default.
• W2578265208 cites W2046235254 @default.
• W2578265208 cites W2065378903 @default.
• W2578265208 cites W2067946566 @default.
• W2578265208 cites W2088788142 @default.
• W2578265208 cites W2093296730 @default.
• W2578265208 cites W2097632835 @default.
• W2578265208 cites W2105564974 @default.
• W2578265208 cites W2120007033 @default.
• W2578265208 cites W2123608584 @default.
• W2578265208 cites W2136291464 @default.
• W2578265208 cites W2138129937 @default.
• W2578265208 cites W2141130623 @default.
• W2578265208 cites W2142212072 @default.
• W2578265208 cites W2143548516 @default.
• W2578265208 cites W2154310483 @default.
• W2578265208 cites W2156683808 @default.
• W2578265208 cites W2426922988 @default.
• W2578265208 doi "https://doi.org/10.2147/ott.s110281" @default.
• W2578265208 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5238771" @default.
• W2578265208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28138256" @default.
• W2578265208 hasPublicationYear "2017" @default.
• W2578265208 type Work @default.
• W2578265208 sameAs 2578265208 @default.
• W2578265208 citedByCount "4" @default.
• W2578265208 countsByYear W25782652082019 @default.
• W2578265208 countsByYear W25782652082021 @default.
• W2578265208 countsByYear W25782652082022 @default.
• W2578265208 crossrefType "journal-article" @default.
• W2578265208 hasAuthorship W2578265208A5011634104 @default.
• W2578265208 hasAuthorship W2578265208A5030411354 @default.
• W2578265208 hasAuthorship W2578265208A5035915328 @default.
• W2578265208 hasAuthorship W2578265208A5041917929 @default.
• W2578265208 hasAuthorship W2578265208A5048100416 @default.
• W2578265208 hasAuthorship W2578265208A5054620758 @default.
• W2578265208 hasAuthorship W2578265208A5087541016 @default.
• W2578265208 hasAuthorship W2578265208A5091543149 @default.
• W2578265208 hasBestOaLocation W25782652081 @default.
• W2578265208 hasConcept C112705442 @default.
• W2578265208 hasConcept C150903083 @default.
• W2578265208 hasConcept C185592680 @default.
• W2578265208 hasConcept C190283241 @default.
• W2578265208 hasConcept C202751555 @default.
• W2578265208 hasConcept C207001950 @default.
• W2578265208 hasConcept C2775842073 @default.
• W2578265208 hasConcept C2776970183 @default.
• W2578265208 hasConcept C2777151579 @default.
• W2578265208 hasConcept C2777807558 @default.
• W2578265208 hasConcept C2778019345 @default.
• W2578265208 hasConcept C2989005 @default.
• W2578265208 hasConcept C502942594 @default.
• W2578265208 hasConcept C55493867 @default.
• W2578265208 hasConcept C71924100 @default.
• W2578265208 hasConcept C86803240 @default.
• W2578265208 hasConcept C98274493 @default.
• W2578265208 hasConceptScore W2578265208C112705442 @default.
• W2578265208 hasConceptScore W2578265208C150903083 @default.
• W2578265208 hasConceptScore W2578265208C185592680 @default.
• W2578265208 hasConceptScore W2578265208C190283241 @default.
• W2578265208 hasConceptScore W2578265208C202751555 @default.
• W2578265208 hasConceptScore W2578265208C207001950 @default.
• W2578265208 hasConceptScore W2578265208C2775842073 @default.
• W2578265208 hasConceptScore W2578265208C2776970183 @default.
• W2578265208 hasConceptScore W2578265208C2777151579 @default.
• W2578265208 hasConceptScore W2578265208C2777807558 @default.
• W2578265208 hasConceptScore W2578265208C2778019345 @default.
• W2578265208 hasConceptScore W2578265208C2989005 @default.
• W2578265208 hasConceptScore W2578265208C502942594 @default.
• W2578265208 hasConceptScore W2578265208C55493867 @default.
• W2578265208 hasConceptScore W2578265208C71924100 @default.
• W2578265208 hasConceptScore W2578265208C86803240 @default.
• W2578265208 hasConceptScore W2578265208C98274493 @default.
• W2578265208 hasLocation W25782652081 @default.
• W2578265208 hasLocation W25782652082 @default.
• W2578265208 hasLocation W25782652083 @default.

• next